Of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome

被引:96
作者
Bloom, BT
Kattwinkel, J
Hall, RT
Delmore, PM
Egan, EA
Trout, JR
Malloy, MH
Brown, DR
Holzman, IR
Coghill, CH
Carlo, WA
Pramanik, AK
McCaffree, MA
Toubas, PL
Laudert, S
Gratny, LL
Weatherstone, KB
Seguin, JH
Willett, LD
Gutcher, GR
Mueller, DH
Topper, WH
机构
[1] UNIV VIRGINIA, RICHMOND, VA USA
[2] CHILDRENS MERCY HOSP, KANSAS CITY, MO 64108 USA
[3] UNIV MISSOURI, KANSAS CITY, MO 64110 USA
[4] ONY INC, AMHERST, NY USA
[5] RUTGERS STATE UNIV, PISCATAWAY, NJ USA
[6] UNIV TEXAS, MED BRANCH, GALVESTON, TX 77550 USA
[7] NEWARK BETH ISRAEL MED CTR, NEWARK, NJ 07112 USA
[8] MT SINAI NEW YORK, NEW YORK, NY USA
[9] UNIV ALABAMA, BIRMINGHAM, AL USA
[10] LOUISIANA STATE UNIV HLTH SCI CTR, SHREVEPORT, LA 71105 USA
[11] UNIV OKLAHOMA, OKLAHOMA CITY, OK USA
[12] UNIV KANSAS, MED CTR, KANSAS CITY, KS 66103 USA
[13] UNIV NEBRASKA, MED CTR, OMAHA, NE USA
[14] VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA, RICHMOND, VA USA
[15] MED RES CTR, KANSAS CITY, MO USA
关键词
respiratory distress syndrome; surfactant; Infasurf; Survanta;
D O I
10.1542/peds.100.1.31
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. To compare the relative safety and efficacy of Infasurf (calf lung surfactant extract; ONY, Inc, Amherst, NY, IND #27169) versus Survanta (Beractant, Ross Laboratories, Columbus, OH) in reducing the acute severity of respiratory distress syndrome (RDS) when given at birth and to infants with established RDS. Design. A prospective, randomized, double-blind, multicenter clinical trial. Setting. Thirteen neonatal intensive care units participated in the treatment arm: seven of these concurrently participated in the prevention arm. Patients. The treatment arm enrolled infants of less than or equal to 2000 g birth weight with established RDS, and the prevention arm enrolled infants of less than or equal to 29 weeks' gestation with birth weights <1250 g. Intervention. Infants were randomly assigned to receive Infasurf (n = 303, treatment arm; n = 180, prevention arm) or Survanta (n = 305, treatment arm; n = 194, prevention arm) in accordance with the Survanta package insert instructions. Outcomes Measures. We projected a 25% reduction between groups in the need for a third dose of surfactant for infants with established RDS, and a 25% reduction in the need for a second dose of surfactant for infants who received prophylactic surfactant. Secondary outcomes included the severity of RDS measured by inspired oxygen concentrations and mean airway pressure, air leaks, complications associated with surfactant administration, and survival to 36 weeks' postmenstrual age without the need for oxygen supplementation. Results. In the treatment arm, there was no difference between groups in the number of infants requiring more than two doses of surfactant. The interval between doses was significantly longer for Infasurf, suggesting an increased duration of treatment effect. The inspired oxygen concentration and mean airway pressure were lower in the Infasurf infants during the first 48 hours in the treatment arm. In the prevention arm, there were no differences with respect to the number of surfactant doses. The dosing intervals were longer for Infasurf infants after the second dose. No difference in inspired oxygen or mean airway pressure was noted during the first 72 hours. There were no significant differences in the incidence of air leaks, complications associated with dosing, complications of prematurity, mortality, or survival without chronic lung disease in the prevention or treatment arm. Conclusions. Infants treated with Infasurf have a modest benefit in the acute phase of RDS. Infasurf seems to produce a longer duration of effect than Survanta.
引用
收藏
页码:31 / 38
页数:8
相关论文
共 28 条
  • [11] A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome
    Hudak, ML
    Farrell, EE
    Rosenberg, AA
    Jung, AL
    Auten, RL
    Durand, DJ
    Horgan, MJ
    Buckwald, S
    Belcastro, MR
    Donohue, PK
    Carrion, V
    Maniscalco, WW
    Balsan, MJ
    Torres, BA
    Miller, RR
    Jansen, RD
    Graeber, JE
    Laskay, KM
    Matteson, EJ
    Egan, EA
    Brody, AS
    Martin, DJ
    Riddlesberger, MM
    Montgomery, P
    [J]. JOURNAL OF PEDIATRICS, 1996, 128 (03) : 396 - 406
  • [12] KATTWINKEL J, 1993, PEDIATRICS, V92, P90
  • [13] A COMPARISON OF SURFACTANT AS IMMEDIATE PROPHYLAXIS AND AS RESCUE THERAPY IN NEWBORNS OF LESS THAN 30 WEEKS GESTATION
    KENDIG, JW
    NOTTER, RH
    COX, C
    REUBENS, LJ
    DAVIS, JM
    MANISCALCO, WM
    SINKIN, RA
    BARTOLETTI, A
    DWECK, HS
    HORGAN, MJ
    RISEMBERG, H
    PHELPS, DL
    SHAPIRO, DL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (13) : 865 - 871
  • [14] KWONG MS, 1985, PEDIATRICS, V76, P585
  • [15] LIECHTY EA, 1991, PEDIATRICS, V88, P19
  • [16] PROPHYLACTIC TREATMENT OF VERY PREMATURE-INFANTS WITH HUMAN SURFACTANT
    MERRITT, TA
    HALLMAN, M
    BLOOM, BT
    BERRY, C
    BENIRSCHKE, K
    SAHN, D
    KEY, T
    EDWARDS, D
    JARVENPAA, AL
    POHJAVUORI, M
    KANKAANPAA, K
    KUNNAS, M
    PAATERO, H
    RAPOLA, J
    JAASKELAINEN, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (13) : 785 - 790
  • [17] SURFACTANT SUPPLEMENTATION IN THE PRETERM RABBIT - EFFECTS OF APPLIED VOLUME ON COMPLIANCE AND SURVIVAL
    METCALFE, IL
    BURGOYNE, R
    ENHORNING, G
    [J]. PEDIATRIC RESEARCH, 1982, 16 (10) : 834 - 839
  • [18] SURFACTANT PROTEIN-B SUPPLEMENTATION IMPROVES IN-VIVO FUNCTION OF A MODIFIED NATURAL SURFACTANT
    MIZUNO, K
    IKEGAMI, M
    CHEN, CM
    UEDA, T
    JOBE, AH
    [J]. PEDIATRIC RESEARCH, 1995, 37 (03) : 271 - 276
  • [19] INCIDENCE AND EVOLUTION OF SUBEPENDYMAL AND INTRA-VENTRICULAR HEMORRHAGE - STUDY OF INFANTS WITH BIRTH WEIGHTS LESS THAN 1,500 GM
    PAPILE, LA
    BURSTEIN, J
    BURSTEIN, R
    KOFFLER, H
    [J]. JOURNAL OF PEDIATRICS, 1978, 92 (04) : 529 - 534
  • [20] RAJU TNK, 1987, LANCET, V1, P651